Day Three, Wednesday, Oct 12

8:30 - 10:10 Session VII: PATHOGENIC MECHANISMS OF NEURODEGENERATION (II)
Chair: Gopal Thinakaran, USF Morsani College of Medicine, USA

8:30 - 8:50 The Amyloid Scaffold Hypothesis of Alzheimer’s Disease
Todd Golde, University of Florida, USA

8:50 - 9:10 Role of the gut microbiome in modulation of Abeta amyloidosis and neuroinflammation
Sangram Sisodia, University of Chicago, USA

9:10 - 9:30 Role of gamma-secretase in innate immunity and AD
Yueming Li, Solan-Kettering Memorial Cancer Center, USA

9:30 - 9:50 Mitochondrial dysfunction in AD
Xiongwei Zhu, Case Western Reserve University, USA

9:50 - 10:10 Chronic Stress & exosomes: key players in progression and diagnosis of AD.
Ioannis Sotiropoulos, ICVS, Greece

10:10 - 10:40 Coffee break/Exhibits

10:40 - 12:20 Session VIII: FROM MECHANISMS TO THERAPIES
Chair: Abraham Fisher, AD/PD™

10:40 - 11:00 Mechanisms and therapeutic insights for neurodegenerative disease
Leonard Petrucelli, Mayo Clinic, USA

11:00 - 11:20 M1 muscarinic stimulation of post-synaptic receptors for the potential treatment and prevention of cognitive decline
Abraham Fisher, AD/PD™

11:20 - 11:40 TDP-43: pathobiology, prognostic biomarker, and therapeutic strategy. Philip Wong, Johns Hopkins University, USA

11:40 - 12:00 Therapeutic strategies targeting alpha-synuclein in AD-related dementia Pamela McLean, Mayo Clinic, USA

12:00 - 12:20 Farnesyltransferase inhibition for Alzheimer’s disease
Robert Vassar, Northwestern University, USA

12:20 - 12:35 BRIGHTFOCUS FOUNDATION TRAVEL FELLOWSHIP AWARD CEREMONY
Diane Bovenkamp, BrightFocus Foundation, USA

12:35 - 13:00 SHORT TALK/POSTER AWARDS AND CLOSING REMARKS